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ABSTRACT
In models of Parkinson’s disease (PD), Rho kinase (ROCK) inhibitors have antiapoptotic and axon-
stabilizing effects on damaged neurons, decrease the neuroinflammatory response, and protect
against dopaminergic neuron death and axonal retraction. ROCK inhibitors have also shown protec-
tive effects against apoptosis inducedbyhandling anddissociationof several types of stemcells. How-
ever, the effect of ROCK inhibitors on dopaminergic cell grafts has not been investigated. In the
present study, treatment of dopaminergic cell suspensionwith ROCK inhibitors yielded significant de-
creases in the number of surviving dopaminergic neurons, in the density of graft-derived dopaminer-
gic fibers, and in graft vascularization.Dopaminergic neurondeath alsomarkedly increased inprimary
mesencephalic cultures when the cell suspension was treated with ROCK inhibitors before plating,
which suggests that decreased angiogenesis is not the only factor leading to cell death in grafts. In-
terestingly, treatment of the host 6-hydroxydopamine-lesioned rats with ROCK inhibitors induced a
slight, nonsignificant increase in the number of surviving neurons, as well as marked increases in the
density of graft-derived dopaminergic fibers and the size of the striatal reinnervated area. The study
findings discourage treatment of cell suspensions before grafting. However, treatment of the host
induces a marked increase in graft-derived striatal reinnervation. Because ROCK inhibitors have also
exerted neuroprotective effects in several models of PD, treatment of the host with ROCK inhibitors,
currently used against vascular diseases in clinical practice, before and after grafting may be a useful
adjuvant to cell therapy in PD. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:804–815
SIGNIFICANCE
Cell-replacement therapy is one promising therapy for Parkinson’s disease (PD). However, many
questionsmust be addressed beforewidespread application. Rho kinase (ROCK) inhibitors have been
used in a variety of applications associated with stem cell research and may be an excellent strategy
for improving survival of grafted neurons and graft-derived dopaminergic innervation. The present
results discourage the treatment of suspensions of dopaminergic precursors with ROCK inhibitors in
the pregrafting period. However, treatment of the host (patients with PD) with ROCK inhibitors, cur-
rently used against vascular diseases, may be a useful adjuvant to cell therapy in PD.
INTRODUCTION
Consistent with the antiapoptotic properties of
Rho kinase (ROCK) inhibition [1], ROCK inhibitors
have been used in a variety of applications asso-
ciatedwith cell dissociation in the process of stem
cell research, such as passaging, expansion, cryo-
preservation, gene transfer, inductionof differen-
tiation, andcell sorting. It hasbeen suggested that
ROCK inhibitorsmay constitute an important tool
for improving the handling of human inducedplu-
ripotent stem (iPS) cells and embryonic stem (ES)
cells [2, 3], mouse ES cell-derived neural precur-
sors [4], mouse intestinal stem cells [5], human
keratinocytes [6], and bone marrow mesenchy-
mal cells [7]. In contrast, ROCK inhibitors have
detrimental effects on the expansion and survival
of both fresh and cryopreserved cells [8–11].
One promising therapeutic approach for
Parkinson’s disease (PD) is cell-replacement ther-
apy, in which dopaminergic precursors are grafted
into the striatum to restore the lost dopaminergic
neurotransmission. However, many questions,
including theuseof sources of cells other thanpri-
mary tissue (i.e., ES cells or iPS cells), must be
addressed before widespread application of the
treatment is possible [12–16]. A major limiting
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neurons. Furthermore, axonal outgrowth from the grafted neu-
rons, which is important for clinical efficacy, is often poor, partic-
ularly outgrowth fromneurons obtained from sources other than
primary tissue. Independently of the cell source, strategies for im-
proving survival of grafted cells and graft-derived dopaminergic
innervation are therefore required [17, 18].
ROCK inhibitionhas antiapoptotic and axon-stabilizing effects
in damaged neurons [19]. ROCK inhibitors also show anti-
inflammatory properties via their effects on migration, phagocy-
tosis, and several othermechanisms involved in the inflammatory
response in the central nervous system (CNS) and other tissues
[20, 21]. ROCK signaling is also an importantmediator inmany an-
giogenic processes, including migration, survival, and permeabil-
ity of endothelial cells [22]. All of thesemechanisms (reviewed by
Labandeira-Garcia et al. [23]) play critical roles in the growth and
functional effects of dopaminergic grafts. Furthermore, recent
studies in PD models have shown that ROCK inhibitors protect
against dopaminergic neuron death and axonal retraction in-
duced by dopaminergic neurotoxins [23]. However, no studies
have yet considered the effects of ROCK inhibitors on dopaminer-
gic cell grafts. The current study investigated this aspect by treat-
ing suspensions of dopaminergic precursors destined for grafting
andhost animals (rats lesionedwith thedopaminergic neurotoxin
6-hydroxydopamine [6-OHDA]) with ROCK inhibitors. We also
used primary cultures of dopaminergic neurons to clarify the
mechanisms involved in the observed effects.
MATERIALS AND METHODS
In Vitro and In Vivo Treatment With ROCK Inhibitors
In vitro, we tested the effects of Y-27632, which is the ROCK in-
hibitor commonly used for improving handling of different types
of cells. In rats, we tested the effects of fasudil, which is the ROCK
inhibitor commonly used for in vivo studies. Fasudil is the only
ROCK inhibitor approved for clinical use (approved in Japan since
1995). Y-27632 is a potent ROCK inhibitor, which is also active af-
ter oral administration, but it is metabolized rapidly and its brain
penetration might be too low to achieve therapeutical levels for
CNS diseases. However, Y-27632 is a more potent inhibitor and
exhibits more favorable selectivity profile than fasudil for in vitro
studies [24]. We performed additional in vitro experiments with
fasudil to confirmmajor results obtained with Y-27632 and to ex-
clude any possible difference between the effects of both
inhibitors.
In Vivo Experiments: Experimental Design
Eight-week-old female Sprague-Dawley ratswere used. All exper-
iments were carried out in accordance with the European Com-
munities Council Directive 2010/63/EU and Directive 86/609/
EEC and were approved by the corresponding committee at the
University of Santiago de Compostela. Rats were subjected to a
prelesion cylinder test (discussed later in this paragraph). Rats
were then subjected to maximal unilateral dopaminergic dener-
vation with 6-OHDA (discussed later in this paragraph). One
month after injectionwith 6-OHDA, ratswithmaximal lesions (to-
tal or almost total dopaminergic depletion;.90%)were selected
in the rotometer test after administration of apomorphine (0.05
mg/kg subcutaneously; Sigma-Aldrich, St. Louis, MO, https://
www.sigmaaldrich.com/) [25]. One week after the rotometer
test, the rats with maximal lesions (n = 34) were subjected to a
postlesion cylinder test and were again tested in the rotometer
after administration of D-amphetamine (5 mg/kg in saline intra-
peritoneally; Sigma-Aldrich). One week after the last postlesion
behavioral test, the ratswere randomly divided into 2 experimen-
tal groups to investigate the effect of the ROCK inhibitors. Rats in
group A (n = 17; 3 subgroups) were used to study the effect of
ROCK inhibitor Y-27632 on survival of grafted fetal ventral mes-
encephalon (VM) cell suspensions. One subgroup of rats (A1,
Y-27632 group; n = 6) received a VM cell suspension containing
30mΜY-27632 (Sigma-Aldrich). Thedoseof Y-27632was selected
in accordance with the results of previous studies [26–32]. An-
other subgroup of rats (A2, control group; n = 6) was grafted with
the same VM cell suspension containing vehicle. The third sub-
group (A3, shamgroup; n = 5)was shamgraftedwith vehicle. Rats
in group B (n = 17; 3 subgroups) were used to test the effect of the
ROCK inhibition in the host rats on survival of grafted VM precur-
sors. Rats in subgroupB1 (fasudil group;n = 6)were graftedwith a
cell suspension from the VM and were also administered the
ROCK inhibitor fasudil (30 mg/kg per day; LC Laboratories,
Woburn, MA, http://www.lclabs.com/) in their drinking water
from 15 days before receiving the cell implants until they were
killed. The dose of fasudil was selected in accordance with the re-
sults of previous studies [27, 33–35]. Rats in subgroupB2 (control;
n = 6) were grafted with the same VM cell suspension and admin-
istered vehicle in their drinking water during the same period as
subgroup B1. Rats in subgroup B3 (sham group; n = 5) were sham
grafted with vehicle and treated orally with vehicle. Six weeks af-
ter grafting, the rats were again tested in the cylinder and the
rotometer and were then killed for histological analysis.
6-OHDALesionandTransplantation Surgery: Behavioral
Testing of Lesion Efficacy and Graft Survival
Unilateral lesions of the dopaminergic systemwere performed by
injection into the right medial forebrain bundle of 12 mg of
6-OHDA hydrobromide (Sigma-Aldrich). The stereotaxic coordi-
nates were 3.7 mm posterior to the bregma, 21.6 mm lateral
tomidline, and 8.8mmventral to the skull [36]. Rats in subgroups
A1,A2, B1, andB2 (i.e., rats transplantedwithprimary fetal tissue)
received intrastriatal injections of cell suspensions prepared from
fetal (13 days of gestation, E13) VM. The pieces of VM were dis-
sected out and incubated in 0.1% trypsin (Sigma-Aldrich), 0.05%
DNase (Sigma-Aldrich), and Dulbecco’s Modified Eagle’s Me-
dium (DMEM; Thermo Fisher Scientific Life Sciences, Waltham,
MA, http://www.thermofisher.com) for 20 minutes at 37°C.
The tissuewas then rinsed inDNase/DMEMandmechanically dis-
sociated to obtain a cell suspension with a final concentration of
150,000 cells/ml. Rats in subgroup A1were graftedwith a VM cell
suspension containing 30mΜ Y-27632,whichwas addedafter cell
dissociation. A total of 3 ml of cell suspension from primary fetal
tissue was administered to each rat at a single injection site (an-
terior to bregma, 0.6mm; lateral to midline,22.7mm; ventral to
the skull, 4.5 mm).
The efficacy of the lesion and graft survival was evaluated by
the rotometer test (i.e., maximally lesioned rats) [25] and the cyl-
inder test [37], and theywere confirmed by subsequent immuno-
histochemistry (seediscussion later in text). Turning behaviorwas
monitored for 90minutes after injection of D-amphetamine or for
60 minutes after injection of apomorphine. Spontaneous fore-
limb use was assessed by an observer blinded to the identity of
the animals, who scored the number of forelimb contacts with
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the cylinder wall, recording a total number of 20 touches for each
animal. Forelimb asymmetry, assessed as use of the left impaired
paw,wasexpressedaspercentageof the total numberof touches.
Immunolabeling and Quantitative Histological Analysis
At 6 weeks after grafting, the animals were perfused with 4%
paraformaldehyde and the brains were cut into 40-mm sections.
Seriesof free-floating sectionswereprocessed for amousemono-
clonal antibody to tyrosine hydroxylase (TH; dopaminergic
marker; 1:10,000; Sigma-Aldrich) or a mouse monoclonal antise-
rum to rat endothelial cell antigen-1 (RECA-1;marker of rat endo-
thelial cells; 1:2,000; AbD Serotec, Oxford, U.K., https://www.
abdserotec.com). The labeling was visualized by using 3,39diami-
nobenzidine (DAB; Sigma-Aldrich). Additional series of sections
containing the transplants were processed for double immuno-
labeling against TH and RECA-1 using the immunoperoxidase
technique.
Quantification of TH-immunoreactive (-ir) neurons or RECA-
1-positive microvessels in grafts was carried out in every fourth
section to cover the entire graft from the rostral tip to the caudal
end. Sampling was carried out with the Computer Assisted
Stereological Toolbox (CASTGrid system;Olympus, Ballerup, Den-
mark, http://www.olympus.dk/). The total numbers of TH-
positive neurons and RECA-1-positive microvessels in the grafts
were calculated according to the optical fractionator equation
[38]. The graft volume was estimated according to Cavalieri’s
method [39]. The striatal graft-derived reinnervation area (TH-
ir area surrounding the graft) was measured by using the CAST-
Grid system. At least four sections through the grafted striatum
of each rat were measured and expressed in mm2. The density
of the TH-ir fibers in the graft-derived reinnervation area was es-
timated as the optical density of striatal TH-ir with the aid of Im-
age 1.55 image analysis software (National Institutes of Health,
Bethesda, MD, http://imagej.nih.gov). At least four sections
through the graft of each animal were measured, and for each
section optical density was corrected by subtraction of back-
ground as observed in the corpus callosum.
In Vitro Experiments: Primary Mesencephalic Cultures
and Cell Suspensions
VMtissuewasdissected fromrat embryos (E13) andmechanically
dissociated, and the resulting cell suspension was treated as de-
scribed previously [40]. The primary mesencephalic cell cultures
weremaintained in a humidified CO2 incubator (5%CO2, 37°C) for
7 days in vitro (DIV). To study the possible involvement of ROCK in
dopaminergic survival, primary cultures were treated with the
ROCK inhibitors Y-27632 or fasudil under different experimental
conditions. In a first groupof cultures (group1), Y-27632or fasudil
(10 or 30 mΜ) was added 1 hour before cell dissociation
(i.e., previously toobtain a single cell suspension fromVMpieces).
Some cultures (group 2) were treated with Y-27632 or fasudil
1 hour before dissociation and after dissociation (i.e., previously
to obtain a single cell suspension and added into the culture me-
diumat plating). Cultures of group 3were treatedwith Y-27632or
fasudil only after dissociation (i.e., at plating). Group 2 and 3 cell
cultures were maintained for 2 DIV in the presence of Y-27632 or
fasudil (i.e., until the culture medium was replaced with fresh
medium). Some primary cultures (group 4) were treated with
Y-27632 or fasudil (30mM) on 7 DIV for 24 hours. Finally, a group
of cell suspensions were treated with Y-27632 (30 mM) or fasudil
(30mM) for up to 24hours, and cell survival was estimated before
plating by methylthiazolyldiphenyl-tetrazolium bromide (MTT)
assay as follows. After treatment with ROCK inhibitors Y-27632
(30 mM) or fasudil (30 mM) for 30 minutes or 2, 4, or 24 hours,
cellswere incubatedwithMTT (1mg/ml) for 4 hours at 37°C. After
removing theMTT in the supernatant, the formazan crystals were
dissolved in acidic isopropanol andquantified using aplate reader
at 570 nm (Tecan Infinite M200, Grödig, Austria, http://
lifesciences.tecan.com).
Immunocytochemistry and Cell Counts
Cultures were fixed with 4% paraformaldehyde and incubated
with a mouse monoclonal anti-TH (1:30,000). The labeling was
revealed with DAB. TH-ir cells, observed by phase-contrast mi-
croscopy (magnification, 3100; Eclipse, Nikon, Tokyo, Japan,
https://www.nikoninstruments.com), were counted in 5 ran-
domly chosen longitudinal and transverse microscopic fields
along the diameter of the culture dish. The microscopic field
was defined by a 0.5-cm 3 0.5-cm reticule (i.e., a total of 1.25
cm2). The results from at least 3 different experiments were
recorded. The results were normalized to the counts of the con-
trol group in the sameexperiment (i.e., expressed as apercentage
of the control group counts). In addition, neurons from control
cultures and mature cultures treated with fasudil or Y-27632
(30 mM, on 7 DIV for 24 hours) were randomly selected, and
the lengths of primary processes of every neuron examined were
measured with the aid of NIH-Image analysis software. A mini-
mum of 75 processes from 3 independent experiments was
measured per treatment group. Clusters of cells in which primary
processes were not clearly distinguished were excluded, and
the length of a primary process was defined as the distance from
the soma to the tip of the longest branch [26].
Statistical Analysis
Two-group comparisonswere carried out by using the Student’s t
test. Multiple comparisons were analyzed by one-way analysis of
variance followed by Bonferroni post hoc test. The normality of
populations and homogeneity of variances were tested before
each analysis of variance. The results are presented as means
6 SEM. Differences were considered statistically significant at
p , .05. All statistical analyses were performed with SigmaPlot
11.0 (Systat Software Inc., San Jose, CA, https://systatsoftware.
com/).
RESULTS
ROCK Inhibition of Cell Suspension Destined for
Grafting: Effects on Dopaminergic Neuron Survival and
Striatal Reinnervation
In vivo analysis of amphetamine-induced rotational response 6
weeks after grafting showed no significant differences in post-
grafting rotations of sham-operated animals and of rats after
6-OHDA lesion (1,2576 222.8 turns and 1,290.86 161.8 turns,
respectively). However, net rotations decreased markedly in rats
that received control cell suspensions and rats that received cell
suspensions treated with the ROCK inhibitor Y-27632 (343.2 6
68.9 turns and 423.2 6 45.1 turns, respectively) relative to the
values recorded for these groups after lesion (1,479.9 6 234.8
turns and 1,3096 112.1 turns, respectively). This indicated that
a significant number of grafted dopaminergic neurons had
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survived. However, it is known that even a relatively low number
of surviving dopaminergic neurons can totally reverse the rota-
tional asymmetry, and a postmortem morphological analysis
was necessary to evaluate possible differences in graft develop-
ment. In the cylinder test, no significant recovery was observed
6weeks after lesion in sham-operated animals related toprevious
values (i.e., 4% 6 1.9% and 5% 6 3.2% of left paw use, respec-
tively; subgroupA3). However, use of the impaired paw improved
significantly in rats that received the untreated VM cell suspen-
sion (i.e., 11% 6 5.1% and 39% 6 8.4% of left paw use before
and after grafting, respectively; subgroup A2). Animals that re-
ceived the cell suspension treated with Y-27632 did not show a
significant improvement in values of impaired paw use compared
with the pregrafting values (17%6 5.2% and 31%6 10.1% of left
paw use; subgroup A1).
As observed in previous immunohistochemical studies, TH-ir
neurons were not evenly distributed within the graft but were
usually grouped in patches located at the periphery of the graft,
whereas the central area of the grafts was usually TH-negative
(Fig. 1A). Although the distribution of TH-ir cells in graft of rats
that received cells suspensions treated with Y-27632 was similar
to that in control grafts, the number of dopaminergic cells was
significantly lower than the standard reference (i.e., control
group; 5,405.3 6 880.8 TH-positive cells in control group and
2,117.5 6 388.9 TH-positive cells in Y-27632-treated group)
(Figs. 1, 2A). The average graft volume in the Y-27632-treated
group was lower than that observed in animals grafted with non-
treated cell suspensions (i.e., control group), although the differ-
ence was not statistical significant (0.306 6 0.089 mm3 in
Y-27632-treated group and 0.4486 0.097mm3 in control group).
Grafts in rats that received transplants of control VM precursors
extended numerous processes into the host striatum, and the
graft was surrounded by a TH-ir area (i.e., reinnervation area)
(Fig. 1A, 1C). However, in the Y-27632-treated group (Fig. 1B,
1D), both the reinnervated area and the striatal TH-ir fiber density
were significantly lower than in control grafted animals (a de-
crease of about 50% in the reinnervation area and about 60%
in the striatal TH-ir density) (Figs. 1, 2B, 2C).
ROCK Inhibition in the Host Rats: Effects on
Dopaminergic Neuron Survival and
Striatal Reinnervation
In the rats subjected to maximal dopaminergic denervation with
6-OHDA, evaluation of amphetamine-induced rotational behav-
ior displayed intense rotation toward the denervated side
(1,065.8 6 111.8 turns for control-grafted group, 1,312 6
185.9 turns for the group that then was treated with fasudil,
and 1,290.46 161.8 turns for sham group). Six weeks after graft-
ing, evaluation of the amphetamine-induced rotational behavior
Figure 1. Photomicrographs of intrastriatal ventral mesencephalic (VM) grafts. Immunoreactivity (-ir) against tyrosine hydroxylase (TH) in rats
subjected to unilateral dopaminergic denervation and graftingwith VMcell suspensions (i.e., control;A, C), or with VMcell suspensions treated
with theRhokinase inhibitor Y-27632 (30mM;B,D). In control grafts, numerousTH-ir neurons are located in theperiphery of thegrafts, andTH-ir
fibers innervate the striatal area surrounding the grafts (i.e., reinnervation area). However, the number of TH-ir cells and the density of TH-ir
fibers in the reinnervated area were significantly lower in the Y-27632-treated grafts. Scale bar = 1.5 mm (A, B) and 200 mm (C, D).
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www.StemCellsTM.com ©AlphaMed Press 2016
revealed that the intense ipsiversive rotation observed after the
6-OHDA lesion was significantly reduced in animals that received
a suspensionofVMprecursors (6556161.8 turns for the control/
untreated grafted group and 587.56 167.9 turns for the fasudil-
treated group), whereas no significant decrease in rotational be-
haviorwas observed in sham-grafted rats (1,330.46136.2 turns).
Similarly, in the cylinder test both transplanted groups showed
significant recovery of left paw use relative to the pregrafting
(i.e., postlesion) values (10%64.1%and43.8%67.7% in the con-
trol grafted group; 15%6 6.1% and 56.3%6 15.6% in the fasudil-
treated group). No significant improvement was observed in
sham-operated animals relative to the postlesion values (9% 6
4% and 5% 6 1.6% of left paw use).
Rats with control VM implants showed numerous TH-ir cells
concentrated in the periphery of the graft. The distribution of
TH-ir cells in grafts from animals treated with fasudil was similar
to that observed in the control group. The total number of TH-ir
neurons was apparently higher in fasudil-treated rats, although
the increase was not statistically significant (6,205.8 6 947.1
TH-positive cells in the control group and 7,156.7 6 806.5 TH-
positive cells in the fasudil-treated group) (Figs. 3, 4A). The aver-
age graft volume in the fasudil-treated groupwasnot significantly
different from that observed in untreated rats (i.e., control group;
0.441 6 0.065 mm3 in the fasudil-treated group and 0.486 6
0.038 mm3 in the control group). In both control and fasudil-
treated groups, numerous processes grew from the grafts into
the host striatum, producing a TH-ir area (i.e., reinnervation area)
surrounding the graft. Interestingly, in the fasudil-treated group,
the reinnervated area was significantly larger than that in control
grafted rats (around 80% increase) (Figs. 3C, 3D, 4B). There was
also a significant increase in the density of striatal TH-ir fibers
in the reinnervated area in the fasudil-treated group relative to
the control group (an approximately 70% increase) (Fig. 4C).
Effect of ROCK Inhibition on Graft Microvessels
Control grafts showed tubular structures positive for RECA-1,
forming widely ramified networks that covered the graft (Fig.
5A, 5B). When VM cell suspensions were treated with the ROCK
inhibitor Y-27632 before grafting, a significant decrease in the
number of blood microvessels was observed relative to the con-
trol group (259.767.6 vessels/mm2 in control groupand203.96
19.1 vessels/mm2 in Y-27632-treated group) (Fig. 5C–5E). How-
ever, treatment of the host with the ROCK inhibitor fasudil had
no significant effect on the number of RECA-1-positive vessels
in the graft (250.2 6 28.4 vessels/mm2 in the control group
and 242.1 6 15.5 vessels/mm2 in the fasudil-treated group)
(Fig. 5C, 5F, 5G).
Effect of ROCK Inhibition on Dopaminergic Neuron
Survival in Vitro
Control cultures showed numerous TH-ir neurons and the average
number of TH-positive cells in a control culture dish was 5,0596
226. However, the number of TH-ir cells decreased significantly
(a decrease of approximately 60%) when the mesencephalic cell
suspension was treated with 30 mM Y-27632 after dissociation
(i.e., at plating) (Figs. 6A, 7A, 7B). Cultures treated with lower dose
of Y-27632 (10 mM) showed a low, nonsignificant decrease in the
number of TH-ir cells as control cultures. To confirm that this effect
was related to the timing of treatment, primary cultures were
treated with the ROCK inhibitor Y-27632 (30 mM) for 24 hours at
7 DIV. In this case, no significant differences in the number of do-
paminergic neurons were observed in cultures treated with
Y-27632 relative to the control group (Figs. 6A, 7D). To studywhether
Figure 2. Quantitative histological analysis of intrastriatal grafts of
ventral mesencephalic (VM) cell suspensions treated and not treated
with the Rho kinase inhibitor Y-27632 (30 mM). (A): Number of dopa-
minergic neurons (i.e., TH-positive neurons). (B): Reinnervation area
(i.e., striatal host area innervated by graft-derived TH-ir fibers). (C):
Density of TH-ir fibers in reinnervated area estimated as a optical den-
sity and expressed as a percentage of the value obtained in the control
group. Data represent mean 6 SEM. p, p , .05 relative to control-
grafted rats (Student’s t test). Abbreviations: OD, optical density; TH,
tyrosine hydroxylase; TH-ir, immunoreactive tyrosine hydroxylase.
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treatment with ROCK inhibitors affects dissociation-induced cell
death, cells were treated with Y-27632 either before (only) or be-
fore and after dissociation. Treatment with 30mMY-27632 before
cell dissociation or before and after dissociation significantly re-
duced the number of TH-ir cells in culture. However, the number
of TH-ir cells was similar to the control group in cultures treated
with 10 mM Y-27632 added before (only) or before and after dis-
sociation (Figs. 6B, 7C). Furthermore, some cultures were treated
with fasudil to confirm the effects of Y-27632 and to exclude any
possible particular effect of Y-27632 on dopaminergic neuron via-
bility (Fig. 6C, 6D). Similar to observations after treatment with
Y-27632, the number of TH-ir cells decreased significantly when the
mesencephalic cell suspensionwas treatedwith 30mM fasudil be-
fore and/or after (i.e., at plating) cell dissociation, whereas a lower
dose of fasudil (10 mM) induced a low, nonsignificant decrease in
the number of TH-ir cells. However, cultures treated with fasudil
(30 mM) for 24 hours at 7 DIV did not show significant differences
in the number of dopaminergic neurons relative to the control
group. Consistent with previous studies [26], no significant change
in the lengthof dopaminergic neuriteswasobserved inmature cul-
tures (i.e., on 7 DIV) treated with the ROCK inhibitor Y-27632 (con-
trol: 100%6 5.75%; Y-27632: 97.87%6 7.06%) or fasudil (control:
100% 6 4.51%; fasudil: 109.77% 6 4.44%) relative to untreated
cultures (i.e., controls).
Cell suspensions treated (30minutes–24 hours) with Y-27632
(30 mM) or fasudil (30 mM) and analyzed for cell viability did not
showany significantdifference in cell survival (asmeasuredby the
MTT assay) relative to untreated controls (Fig. 6E, 6F).
DISCUSSION
Cell Therapy in Parkinson’s Disease: Effects of
ROCK Inhibition
The results of open-label clinical trials [41, 42] and double-
blind, placebo-controlled trials [43, 44] indicate that replace-
ment of dopamine-producing neurons may be useful, but
also that many questions must be addressed before wide-
spread application of the treatment is possible [45–47]. Inde-
pendently of the cell source, strategies to improve axonal
growth and survival of grafted cells are required. Data from
previous studies suggest that ROCK inhibitors may improve
the survival of grafted neurons and axonal outgrowth. How-
ever, we observed different effects after treatment of cell sus-
pensions of dopaminergic precursors or host animals with
ROCK inhibitors. In the present study, all grafted rats showed
significant graft-induced recovery in rotational behavior and
the cylinder test. However, it is known that a small number
Figure 3. Photomicrographs of intrastriatal ventral mesencephalic (VM) grafts. Immunoreactivity (-ir) against tyrosine hydroxylase (TH) in rats
subjected to unilateral dopaminergic denervation and grafting with VM cell suspensions (i.e., control; A, C), or with VM cell suspensions trans-
planted in rats treated with the Rho kinase inhibitor fasudil (B, D). Numerous TH-ir neurons are located in the periphery of the grafts, and TH-ir
fibers innervate the striatal area surrounding the grafts (i.e., reinnervation area) both in control and fasudil-treated groups. However, in the
fasudil-treated group the reinnervated area and the density of striatal TH-ir fiberswere significantly higher than in the control group. Scale bar =
1.5 mm (A, B) and 200 mm (C, D).
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of surviving dopaminergic neurons can reverse the rotational
behavior [48, 49]. More sophisticated behavioral methods
must be found in the future to demonstrate functional differ-
ences between grafts in rats [50].
ROCK Inhibition and Dopaminergic Cell Death
It has been suggested that dissociation of neural precursor cells
elicits an intrinsic pathway of cell death that is at least partiallyme-
diated through the r/ROCK pathway, and ROCK inhibitors rescue
these cells, as well as iPS and ES cells, from dissociation-induced
apoptosis and from passing and cryoinjury [2, 4, 51–53]. However,
we observed detrimental effects of treatment of the cell suspen-
sionofdopaminergicprecursorswithROCK inhibitors,which iscon-
sistent with findings of other studies [8, 9]. The detrimental effects
were observed when the dopaminergic precursors were treated
before plating (i.e., before or after dissociation) and were not ob-
served when the ROCK inhibitor was added to mature cultures
(i.e., at 7DIV). This suggests that ROCK inhibition is particularly det-
rimental in cells that have to migrate and become attached, as in
primary cultures and grafts. Consistent with this, we did not find
the detrimental effect of ROCK inhibition in cell suspensions that
were not plated. The effect of ROCK inhibitors may also depend
on the developmental stage of the cellular population and on dis-
tinct lineage/tissue-specific cells [8, 11], andmaybemoreeffective
on iPS and ES cells than on the dopaminergic precursors.
In PDmodels, recent studies carried out in our laboratory [21,
26–28]andothers [20,34]haveshownthatROCK inhibitorsprotect
against dopaminergic neuron death and axonal retraction induced
bydopaminergicneurotoxins (reviewedbyLabandeira-Garciaetal.
[23]). In the present study, treatment of the host with ROCK inhib-
itors only led to a slight, nonsignificant increase in the number of
survivingdopaminergicneurons.However, it is known that approx-
imately 90% of dopaminergic neurons die within 4 days after
transplantation, and the number remains more stable thereafter
[54, 55]. The present results suggest that, in grafted rats, the role
of neuroinflammation and other factors counteracted by ROCK in-
hibitors in PDmodels are less important than additional factors re-
sponsible for neuronal death during the transplantation process.
This is consistentwith previous findings showing that immunosup-
pression with cyclosporine had no significant effect on survival of
neurons in grafts between rats of the same strain [56]. The protec-
tive effect of ROCK inhibitors related with inhibition of neuroin-
flammation may be more important in grafts between different
rat strains, in grafts in PD patients [43, 44], and in long-term pro-
tection of the graftedneurons [57]. The present results (i.e., no sig-
nificant increase in dopaminergic neuron survival after host
treatment) suggest that inhibition of the host ROCK activity has
onlyminor or no detrimental effects on survival of grafteddopami-
nergic cells in comparisonwith those inducedby inhibitionof ROCK
activity in the cell suspension (i.e., marked decrease in dopaminer-
gic cell survival, possibly related todecreaseddopaminergic cellmi-
gration within the graft, and decreased graft vascularization).
Indopaminergic grafts, after the first fewdaysmostof the sur-
vivingdopaminergic neurons are locatedperipherally andclose to
the diffusible support from the host vasculature [58, 59], whereas
more resistant nondopaminergic (i.e., TH-negative) cells survive
in the center of the graft. Accumulation of dopaminergic neurons
in the periphery of the graft is probably related to the increased
rateofdopaminergic cell death in the centerof thegraft, aswell as
to the ability of the grafted dopaminergic neurons to migrate to-
ward the host “trophic” and/or “tropic” substances [58, 60].
Treatment of the cell suspension with ROCK inhibitors may block
the migratory ability of the dopaminergic precursors, and only
those dopaminergic cells that can reach the periphery of the graft
or those already located in peripheral areas would survive.
Figure 4. Quantitative histological analysis of intrastriatal grafts of
ventral mesencephalic cell suspensions (i.e., control) in rats treated
and not treated with the Rho kinase inhibitor fasudil. (A): Number
of dopaminergic neurons (i.e., TH-positive neurons). (B): Reinnerva-
tion area (i.e., striatal host area innervated by graft derived TH-ir fi-
bers). (C): Density of TH-ir fibers in reinnervation area estimated by
optical density, expressed as a percentage of the value obtained in
the control group. Data represent mean 6 SEM. p, p , .05 relative to
control-grafted rats (Student’s t test). Abbreviations: OD, optical density;
TH, tyrosine hydroxylase; TH-ir, immunoreactive tyrosine hydroxylase.
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ROCK Inhibition and Dopaminergic Axonal Outgrowth
In the present study, axonal outgrowth and striatal reinnervation
increased significantly in host animals treated with ROCK inhibi-
tors, which suggests that ROCK inhibition counteracts axonal col-
lapse and retraction induced in grafted neurons by inhibitory
conditions derived from the host striatum. Axon-stabilizing ef-
fects in damaged neurons have also been suggested as a mecha-
nism of neuronal protection by ROCK inhibition [19, 61]. In
neurons, ROCK activation is involved in axonal collapse and re-
traction in the presence of inhibitory conditions, through
Figure 5. Density ofmicrovessels in intrastriatal ventralmesencephalic (VM) grafts. Double immunolabeling of dopaminergic neurons (i.e., TH-
ir, arrow) andmicrovessels (arrowheads) inVMgrafts (A;magnified inB, asterisk). Thedensity ofmicrovessels in grafts fromsuspensions treated
withY-27632 (C–E)decreased relative tountreated controls. Treatmentofhost ratswith fasudil didnothaveasignificanteffect on thenumberof
RECA-1-positive vessels in the graft (F, G). Scale bar = 200 mm (A) and 100 mm (B–D, F). Data represent number of RECA-1-immunoreactive
vessels per mm2 (mean6 SEM). p, p, .05 relative to control-grafted rats (Student’s t test). Abbreviations: g, grafts; RECA-1, rat endothelial
cell antigen-1; RECA-1-ir, immunoreactive rat endothelial cell antigen-1; TH, tyrosine hydroxylase; THir, immunoreactive tyrosine hydroxylase.
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modulation of myosin light chain, phosphorylation of LIM kinase
and other mechanisms [61–63]. Several recent studies have
shown that neuroinflammation may affect axon regeneration
and growth [64, 65], and inhibition of the host neuroinflamma-
tory response by fasudil may contribute to the observed increase
in host reinnervation. However, we have recently shown that
ROCK inhibitors can directly (i.e., in the absence of glia) inhibit
the axonal retraction induced by neurotoxins in dopaminergic
neurons [26]. In the present and previous studies [26], we ob-
served no significant change in the number of dopaminergic neu-
rons and neurite length in control cultures treated with ROCK
inhibitors after plating. This is consistent with previous studies
showing that the effect of ROCK inhibitors was minimal or com-
pletely absent under permissive conditions and that ROCK
Figure 6. Effect of Rho kinase (ROCK) inhibitors on dopaminergic neuron survival in vitro. Treatment of the ventral mesencephalic cell sus-
pensions with 30 mM Y-27632 (A) or 30 mM fasudil (C) after dissociation (i.e., at plating) induced a significant loss of dopaminergic neurons
(i.e., TH-ir cells). No significant differences in the number of TH-ir cells were observed after treatment with the same dose of Y-27632 or fasudil
at 7DIV relative to the control group (A, C). ROCK inhibition (30mMY-27632 or fasudil) before or before and after dissociation also significantly
reduced thenumber of TH-ir neurons in vitro (B,D). However, lower doses of ROCK inhibitors (10mM)didnot induce a significant decrease in the
survival of TH-ir cells. Cell suspensions treated (30 min–24 hours) with Y-27632 (30 mM; D) or fasudil (30 mM; E) and analyzed for cell viability
before plating did not show any significant difference relative to untreated controls. Data represent mean6 SEM. p, p, .05 relative to control
cultures (one-way analysis of variance followed by Bonferroni post hoc test inA–D and Student’s t test in E and F). Abbreviations: 7DIV, 7 days in
vitro; TH-ir, immunoreactive tyrosine hydroxylase.
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inhibition appeared to decrease axonal retraction or stimulate
growth on inhibitory substrates only (i.e., such as the host stria-
tum), rather than causing a general effect of basal promotion of
axonal extension regardless of the substrate [19, 61].
ROCK Inhibition and Graft Vascularization
Angiogenesis is largely mediated by ROCK. ROCK signaling is an
important mediator in many angiogenic processes, including mi-
gration, survival, and permeability of endothelial cells [66]. In the
present study, a graft vascularization decreased significantly after
treatment of cell suspensions with the ROCK inhibitor Y-27632.
However, no significant decrease in graft vascularization was ob-
served after treatment of the hostwith fasudil. It is generally con-
sidered that vessels in dopaminergic grafts are predominantly
host- and not graft-derived [67, 68]. ROCK inhibition of the cell
suspension may block major graft-derived signals required to
stimulate host vessels to vascularize the graft, leading to de-
creased graft vascularization. In addition, a recent study [69] sug-
gests that donor-derived angiogenesis also contributes to graft
vascularization. As noted earlier for migration of dopaminergic
precursors, treatment of the cell suspensionwith ROCK inhibitors
may block the migratory ability of the vascular precursors, which
may lead to the decrease in graft vascularization. Future studies
are necessary to clarify thesemechanisms and the reason that ad-
ministration of fasudil to the host is less detrimental for graft vas-
cularization than treatment of the cell suspension with the ROCK
inhibitor Y-27632. In any case, the increase in cell death observed
in primary cultures (i.e., independent of vascularization) after
treatment of the cell suspension with ROCK inhibitors before plat-
ing indicates that the effect on graft vascularization is not the only
factor involved in the increase in dopaminergic neuron death ob-
served after treatment of the suspensionwith theROCK inhibitor.
CONCLUSION
The present results discourage the treatment of suspensions of do-
paminergicprecursorswithROCK inhibitors in thepregraftingperiod.
However, this does not exclude possible beneficial effects on han-
dling of stem cells in early stages of development. Treatment of
the host animal with ROCK induced a marked increase in the graft-
derived striatal reinnervation. ROCK inhibitors have also been shown
to exert neuroprotective effects in several models of PD. Treatment
of the host (i.e., PD patients) with ROCK inhibitors, currently used
against vascular diseases in clinical practice, before and after grafting
may be a useful adjuvant treatment to cell therapy in PD.
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